UBS Group
INTS icon

UBS Group’s Intensity Therapeutics INTS Stock Holding History

UBS Group’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3 Hold
1
– – ﹤0.01% 11110
2026
Q2 		$4 Sell
1
-191
-99% -$898 ﹤0.01% 10357
2026
Q1 		$1.13K Sell
192
-824
-81% -$6.73K ﹤0.01% 9614
2025
Q4 		$10.4K Sell
1,016
-4,433
-81% -$45K ﹤0.01% 8222
2025
Q3 		$33.1K Buy
5,449
+5,080
+1,377% +$36.3K ﹤0.01% 7835
2025
Q2 		$2.84K Buy
369
+245
+198% +$5.04K ﹤0.01% 9418
2025
Q1 		$6.1K Buy
124
+3
+2% +$167 ﹤0.01% 8931
2024
Q4 		$5.32K Sell
121
-703
-85% -$51K ﹤0.01% 8677
2024
Q3 		$78.7K Buy
824
+691
+520% +$76.7K ﹤0.01% 6523
2024
Q2 		$16.2K Buy
133
+13
+11% +$1.48K ﹤0.01% 7439
2024
Q1 		$15.7K Buy
120
+100
+500% +$12K ﹤0.01% 7032
2023
Q4 		$4.28K Buy
+20
New +$2.1K ﹤0.01% 7883

Other funds holding INTS

Kingsbury Capital Investment Advisors
Kingsbury Capital Investment Advisors Wilmette, Illinois $106M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Mesirow Financial Investment Management
Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

UBS Group's INTS Position: Q3 2026 in Review

UBS Group held its Intensity Therapeutics (INTS) position steady in Q3 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #11110.

UBS Group first reported a position in INTS in Q4 2023 and has held it in 12 quarters since. The position peaked at $78.7K in Q3 2024. 8 funds tracked by Wall St. Rank hold INTS as of Q3 2026.

  • UBS Group held 1 share of Intensity Therapeutics worth $3 as of Q3 2026.
  • UBS Group left its Intensity Therapeutics share count unchanged in Q3 2026.
  • Intensity Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #11110 holding.
  • UBS Group first reported a position in Intensity Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • UBS Group's Intensity Therapeutics position peaked at $78.7K in Q3 2024.
  • 8 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.